Symmetry Investments LP Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Symmetry Investments LP acquired a new position in United Therapeutics Co. (NASDAQ:UTHR) in the second quarter, Holdings Channel reports. The fund acquired 2,101 shares of the biotechnology company’s stock, valued at approximately $669,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Meiji Yasuda Asset Management Co Ltd. grew its position in United Therapeutics by 1.6% in the 2nd quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock worth $652,000 after purchasing an additional 33 shares in the last quarter. ClariVest Asset Management LLC grew its position in shares of United Therapeutics by 120.0% during the 2nd quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. grew its position in shares of United Therapeutics by 14.0% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 42 shares during the period. Access Investment Management LLC grew its position in shares of United Therapeutics by 0.8% during the 2nd quarter. Access Investment Management LLC now owns 7,265 shares of the biotechnology company’s stock valued at $2,314,000 after acquiring an additional 55 shares during the period. Finally, MBM Wealth Consultants LLC grew its position in shares of United Therapeutics by 2.7% during the 1st quarter. MBM Wealth Consultants LLC now owns 2,241 shares of the biotechnology company’s stock valued at $515,000 after acquiring an additional 59 shares during the period. 94.08% of the stock is owned by institutional investors.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $353.00 on Friday. United Therapeutics Co. has a 12 month low of $208.62 and a 12 month high of $366.08. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $15.66 billion, a P/E ratio of 16.69, a PEG ratio of 1.25 and a beta of 0.57. The firm’s 50 day moving average is $339.19 and its 200 day moving average is $291.68.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.33 by ($0.48). United Therapeutics had a return on equity of 18.82% and a net margin of 40.87%. The firm had revenue of $714.90 million during the quarter, compared to analysts’ expectations of $691.87 million. During the same quarter in the prior year, the company earned $5.24 earnings per share. The business’s revenue for the quarter was up 19.8% compared to the same quarter last year. On average, sell-side analysts anticipate that United Therapeutics Co. will post 24.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $400.00 target price on shares of United Therapeutics in a research report on Thursday, August 1st. Morgan Stanley downgraded shares of United Therapeutics from an “overweight” rating to an “equal weight” rating and increased their target price for the company from $310.00 to $321.00 in a research report on Thursday, July 11th. LADENBURG THALM/SH SH downgraded shares of United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. UBS Group increased their target price on shares of United Therapeutics from $300.00 to $370.00 and gave the company a “buy” rating in a research report on Monday, July 8th. Finally, Oppenheimer increased their target price on shares of United Therapeutics from $400.00 to $575.00 and gave the company an “outperform” rating in a research report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, three have issued a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $350.36.

Insiders Place Their Bets

In other United Therapeutics news, CFO James Edgemond sold 7,802 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82. Following the sale, the chief financial officer now directly owns 3,210 shares in the company, valued at approximately $1,108,766.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, CFO James Edgemond sold 7,802 shares of the firm’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $345.41, for a total transaction of $2,694,888.82. Following the sale, the chief financial officer now owns 3,210 shares in the company, valued at approximately $1,108,766.10. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Martine A. Rothblatt sold 3,600 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $315.97, for a total transaction of $1,137,492.00. Following the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $41,076.10. The disclosure for this sale can be found here. Insiders have sold 110,922 shares of company stock worth $36,541,398 in the last three months. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.